Participant Characteristics and Buprenorphine Dose

REFERENCES

• Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000; 58:143–152.
   PubMed Web of Science ®Google Scholar
• Copenhaver MM, Bruce RD, Altice FL. Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: A review of the empirical evidence. Am J Drug Alcohol Abuse 2007; 33:643–654.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Rosenheck RA, Kosten TR. Office-based treatment for opioid dependence: Reaching new patient populations. Am J Psychiatry 2001; 158:1200–1204.
   PubMed Web of Science ®Google Scholar
• Fudala PF, Yu E, MacFadden W, Boardman C, Chiang CN. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998; 50:1–8.
   PubMed Web of Science ®Google Scholar
• Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Jr, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Renner JA, Jr, Santos E, Casadonte P, Fye C, Stine S, Wang RIH, Segal D. Buprenorphine maintenance treatment of opiate dependence: A multicenter randomized clinical trial. Addiction 1998; 93:475–486.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR, Charuvastra C, Klett J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401–407.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR. Clinical efficacy of buprenorphine: Comparisons to methadone and placebo. Drug Alcohol Depend 2003; 70:S49–57.
   PubMed Web of Science ®Google Scholar
• Ling W, Amass L, Shoptaw S, Annon J, Hillhouse M, Babcock D, A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005; 100:1090–1100.
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009; 104:256–265.
   PubMed Web of Science ®Google Scholar
• Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, Pezawas L, Aschauer HN, Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94:1337–1347.
   PubMed Web of Science ®Google Scholar
• Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181:358–364.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98:441–452.
   PubMed Web of Science ®Google Scholar
• Petitjan S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C, Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62:97–104.
   PubMed Web of Science ®Google Scholar
• Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54:713–720.
   PubMed Web of Science ®Google Scholar
• Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenophine to methadone for treatment of opiate dependence. Addiction 2001; 96:683–690.
   PubMed Web of Science ®Google Scholar
• Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S. Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug Alcohol Depend 2004; 75:37–45.
   PubMed Web of Science ®Google Scholar
• Ling W, Smith D. Buprenorphine: Blending practice and research. J Subst Abuse Treat 2002; 23:87–92.
   PubMed Web of Science ®Google Scholar
• Chiang CN, Hawks R. Development of a buprenorphine-naloxone combination drug for the treatment of drug addiction. In Problems of Drug Dependence 1993, NIDA Research Monograph No. 141. Harris LS, ed. Washington, DC: US Government Printing Office, 1994; 458.
   Google Scholar
• Jones HE. Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect 2004; August:4–19.
   Google Scholar
• Compton PA, Wesson DR, Charuvastra VC, Ling W. Buprenorphine as a pharmacotherapy for opiate addiction. Am J Addict 1996; 5:220–230.
   Web of Science ®Google Scholar
• McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, . The fifth edition of the addiction severity index. J Subst Abuse Treat 1992; 9:199–213.
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. Clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003; 35:253–259.
   PubMed Web of Science ®Google Scholar
• Bickel WK, Stitzer MI, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43:72–78.
   PubMed Web of Science ®Google Scholar
• Bickel WK, Stitzer MI, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988; 247:47–53.
   PubMed Web of Science ®Google Scholar
• Ling W, Shoptaw S, Wesson D, Rawson RA, Compton M, Klett CJ. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr 1997; 175:208–220. PMID: 9467800.
   PubMedGoogle Scholar
• Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Long suffering or prolonged suffering? Time matters. Addiction 2009; 104:1429–1430.
   Web of Science ®Google Scholar
• McCance-Katz E. Office-based buprenorphine treatment for opioid-dependent patients. Harv Rev Psychiatry 2004; 12:321–338.
   PubMed Web of Science ®Google Scholar